Trial · NCT05186818
Registered outcomes11
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
1 to 11 of 11
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Change From Baseline in pVO2 at Week 24 | Baseline to Week 24 | The effect of CK-3773274 on exercise capacity in participants with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) was determined through changes in peak oxygen uptake (pVO2) after 24 weeks of treatment. pVO2 was measured by cardiopulmonary exercise testing (CPET) on a treadmill or bicycle. A higher pVO2 indicates better cardiorespiratory fitness. |
| Secondary | Change From Baseline in KCCQ-CSS at Week 24 | Baseline to Week 24 | The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms. |
| Secondary | Change From Baseline in KCCQ-CSS at Week 12 | Baseline to Week 12 | The effect of aficamten on patient health status was assessed using the Kansas City Cardiomyopathy Questionnaire (KCCQ), a patient-reported outcome designed to assess the physical limitations, symptoms, self-efficacy, social limitation, and quality of life of patients with heart failure symptoms. The KCCQ-Clinical Symptoms Score (KCCQ-CSS) is scored on a scale from 0 to 100, with higher scores indicating better physical functioning and symptoms. |
| Secondary | Proportion of Participants With ≥1 Class Improvement in New York Heart Association (NYHA) Functional Class From Baseline to Week 24 | Baseline to Week 24 | The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 24 weeks of treatment. |
| Secondary | Proportion of Participants With ≥1 Class Improvement in NYHA Functional Class From Baseline to Week 12 | Baseline to Week 12 | The effect of aficamten on NYHA functional classification was evaluated through changes observed from baseline through 12 weeks of treatment. |
| Secondary | Change From Baseline in Valsalva Left Ventricular Outflow Tract Gradient (LVOT-G) at Week 24 | Baseline to Week 24 | The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24. |
| Secondary | Change From Baseline in Valsalva LVOT-G at Week 12 | Baseline to Week 12 | The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12. |
| Secondary | Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 24 | Baseline to Week 24 | The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 24. |
| Secondary | Proportion of Participants With Valsalva LVOT G <30 mmHg at Week 12 | Baseline to Week 12 | The effect of aficamten treatment on Valsalva LVOT-G was evaluated through changes from baseline to Week 12. |
| Secondary | Duration of SRT Eligibility During the 24-week Treatment Period for Participants Who Were SRT Eligible at Baseline | Baseline to Week 24 | The effect of aficamten treatment on the duration of septal reduction therapy (SRT) eligibility was evaluated over the 24- week treatment period. |
| Secondary | Change From Baseline to Week 24 in Total Workload During CPET | Baseline to Week 24 | Effect of aficamten on intensity of exercise (based on speed, incline, participant weight, etc.) during CPET. Workload is an indication of the energy expended during the exercise test. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT05186818/registered